These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 15077129)

  • 41. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
    Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
    An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Poland GA
    Vaccine; 2007 Apr; 25(16):3090-100. PubMed ID: 17280755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
    Pareek M; Pattison HM
    Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.
    Raut SK; Kulkarni PS; Phadke MA; Jadhav SS; Kapre SV; Dhere RM; Dhorje SP; Godse SR
    Clin Vaccine Immunol; 2007 Oct; 14(10):1370-1. PubMed ID: 17699834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Laws HJ; Calaminus G; Göbel U
    Cancer; 2005 Apr; 103(8):1759; author reply 1760. PubMed ID: 15717299
    [No Abstract]   [Full Text] [Related]  

  • 52. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Fioredda F; Giacchino M; Castagnola E
    Cancer; 2005 Apr; 103(8):1758-9; author reply 1760. PubMed ID: 15717298
    [No Abstract]   [Full Text] [Related]  

  • 53. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I; Kontio M; Paunio M; Peltola H
    Expert Rev Vaccines; 2010 Sep; 9(9):1045-53. PubMed ID: 20822347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.
    Nakayama T; Kawamura A; Sogawa Y; Sakakibara S; Nakatsu T; Kimata M; Oe K
    J Infect Chemother; 2024 Dec; 30(12):1289-1294. PubMed ID: 38906375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.